Image Image Image Image Image Image Image Image Image Image
Access
Up

Up

A phase I study to establish the safety and tolerability of ARC1905 (Anti-C5 Aptamer) in subjects with dry age-related macular degeneration
31/12/2011

Foto53_4

The objectives of this study are to evaluate the safety and tolerability of ARC1905 intravitreous injections in subjects with geographic atrophy secondary to dry age-related macular degeneration(AMD). Patients were assigned in an alternating fashion to one of two dose levels of ARC1905: 0.3 or 1 mg/eye. Patients were treated with 3 initial intravitreal injections of ARC1905 at Day 0,Week 4,Week 8, and a followup visit at Week 16. They then received 2 subsequent injections at Week 24 and Week 36, with a final follow-up visit at Week 48. There was a maximum of 5 ARC1905 injections.

RESULTS: Pending analysis data. No safety concerns in this phase I intravitreal use for the first time of aptamer anti C5 for geographic atrophy.

Intravitreal injectionsDry or atrophic AMDExudative or wet AMDRetina scanAutofluorescenceMicroperimetryFluorescein angiographyOptical coherence tomography

Author

Dr. Jordi Monés, M.D., Ph.D.
COMB Medical license number: 22.838
Director
Doctor of Medicine and Surgery
Specialist in Ophthalmology
Specialist in Retina, Macula and Vitreorretinal

Last modified: 29 November, 2021 - 13:07